Will Recent Major Trials With CDK Inhibitors Be Practice Changing In Early Breast Cancer?

Will Recent Major Trials With CDK Inhibitors Be Practice Changing In Early Breast Cancer?

The programme is designed to offer an overview of recent research activities in this area and review the current status and future prospect of CDK4-6 inhibitors in HR-positive/HER2-negative early breast cancer.

Programme

• Welcome and Introduction, Prof. Giuseppe Curigliano, University of Milano, Istituto Europeo di Oncologia, Milan, Italy
• Risk Stratification in ER-positive/HER2-negative Early Breast Cancer: Pathological, Clinical and Genomic Risk, Prof. Lajos Pusztai, Yale Cancer Center, Yale School of Medicine, New Haven, CT, US
• The Impact of CDK 4-6 Inhibitors in the Adjuvant Treatment of ER-positive/HER2-negative High Risk Breast Cancer, Prof. Hope Rugo, Division of Hematology and Oncology, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, US
• Omission of Chemotherapy in the Adjuvant Setting: Optimising Treatment by Risk Stratification, Prof. Giuseppe Curigliano, University of Milano, Istituto Europeo di Oncologia, Milan, Italy
• What Have We Learned From Neoadjuvant CDK4/6 Inhibitor Trials and What Will We Plan for the Future in eBC?, Prof. Sibylle Loibl, GBG Forschungs GmbH, Academic Research Organisation (ARO), Neu-Isenburg, Germany
• Q&A
• Closing Remarks, Prof. Giuseppe Curigliano, University of Milano, Istituto Europeo di Oncologia, Milan, Italy

Learning objectives

• Understand the impact of CDK 4-6 inhibitors in the adjuvant therapy of breast cancer
• Learn how to perform a risk assessment in ER-positive/HER2-negative early breast cancer and how to define risk stratification
• Redefine treatment selection and prioritisation in the adjuvant setting
• Contextualise the results of the neoadjuvant trials with CDK 4-6 inhibitors in early breast cancer